Real-world Trial of Individualized Precision Oncology for Metastatic Cancer

This study is for adults with metastatic (cancer that has spread) or unresectable (cancer that cannot be removed by surgery) solid cancers. It aims to see if a treatment called "Molecularly matched therapy" works better than "Standard of care" drugs. Molecularly matched therapy uses drugs chosen to target specific changes in your tumor's DNA. Researchers want to know if these matched drugs can delay your cancer from getting worse for a longer time compared to standard treatments. The study plans to enroll 280 people, but its current status is unclear. To join, you must be at least 18 years old and have metastatic or unresectable solid cancer with a high risk of death within two years, or your cancer has progressed quickly, or your life expectancy is short.

Study design: This is an interventional study, meaning participants will receive specific treatments. It compares two different drug approaches: Molecularly matched therapy and Standard of care therapy, and plans to enroll 280 participants.
What's involved: You will take either Molecularly matched therapy or Standard of care drugs according to their regular schedule. You will also visit the clinic approximately every two months for checkups and tumor imaging.
Compensation: Not stated in the trial record.
Follow-up: The main goal is to measure how long you live without your cancer getting worse (progression-free survival) at 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Real-world Trial of Individualized Precision Oncology

Not Yet Recruiting

PHASE2Ages 18+InterventionalTreatment

University of California, San Diego

~280 participants

Updated 2026-09-03 on ClinicalTrials.gov

What's tested:Molecularly matched therapyStandard of care

At a glance

Recruiting sites

0 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Progression free survival

Measured over 1 year

Conditions

Metastatic Cancer

Unresectable Carcinoma

NCT07346209

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

University of California, San Diego
La Jolla, Californiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Jason K. Sicklick, MD · PRINCIPAL_INVESTIGATOR · University of California, San Diego

Who to contact

Jason K. Sicklick, MD

[email protected]

(858) 822-5354

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Exclusion

Example 1: Presence of BRAF V600E in lung cancer as the sole molecularly matched target is ineligible, given Food and Drug Administration approval of combination BRAFi/MEKi.

Example 2: Presence of BRAF V600E and CDKN2A mutation in lung cancer is eligible, if the Molecular Tumor Board recommendation is the non-standard of care combination of BRAFi/MEKi + CDK4/6i

Example 3: Presence of KRAS G12C in breast cancer is eligible as the use of KRAS inhibitors for this specific tumor type is not standard of care.

Example 4: Presence of KRAS G12A mutation in colon cancer is eligible if the Molecular Tumor Board recommendation is for non-standard of care MEKi. 6. Newly diagnosed symptomatic brain metastases requiring immediate treatment. Note that patients with asymptomatic or treated stable brain metastases not requiring steroids can be enrolled. 7. Increase of Eastern Cooperative Oncology Group performance status of ≥ 1 point in the 30 days prior to enrollment. 8. Pregnancy or lactation. 9. Known allergic reactions to components of the therapy. 10. Other conditions that preclude study participation at the discretion of the treating physician (e.g., organ or bone marrow dysfunction). 11. Patient is in hospice care. 12. Two oncologists disagree on prognosis or cancer resectability.

What this trial measures

Progression free survival1 year
Duration of time from randomization until objective tumor progression, clinical progression, treatment discontinuation due to inability to tolerate study therapy, or death from any cause.

Trialytics